Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORE-001 oral lidocaine for prevention of postoperative gastrointestinal disturbance after longitudinal laparotomy
2022-503113-31-01Phase 2Completed
- Sponsor
- Orexa
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Not applicable comparing Oral lidocaine (ORE-001) with Placebo (2 arms). Primary endpoint: I-FEED score at postoperative day 3. Started Sep 2023; status: completed.
02
Drugs
lidocaine
03
Conditions
Not applicable
Beyond the preview
Go deeper on 2022-503113-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503113-31-01.